John Wiley & Sons

SHERPA: Green

People

  1. Zelenetz
    Zelenetz
  2. Horwitz
    Horwitz
  3. Palomba
    Palomba
  4. Yahalom
    Yahalom
  5. Moskowitz
    Moskowitz
  6. Noy
    Noy
  7. Hamlin
    Hamlin
  8. Zhang
    Zhang
  9. Perales
    Perales
  10. Giralt
    Giralt

Groups

  1. Center for Hematologic Malignancies (93)
  2. Department of Medicine (93)
  3. Hematologic Malignancies, Division of (93)
  4. Lymphoma (93)
  5. Survivorship Research (23)
  6. Population Sciences Research Program (15)
  7. Executive Committee, Center for Hematologic Malignancies (13)
  8. Biostatistics Service (11)
  9. Epidemiology and Biostatistics (11)
  10. Radiation Oncology, Department of (9)
Search Within
  1. "Lymphoma"
Formats
  1. Journal Article (49)
  2. Meeting Abstract (37)
  3. Research Letter (3)
  4. Editorial (2)
  5. Book Section (1)
  6. Review (1)
Groups
  1. Center for Hematologic Malignancies (93)
  2. Department of Medicine (93)
  3. Hematologic Malignancies, Division of (93)
  4. Lymphoma (93)
  5. Survivorship Research (23)
  6. Population Sciences Research Program (15)

More Groups

People
  1. Andrew Zelenetz (39)
  2. Craig Moskowitz (15)
  3. Steven Horwitz (15)
  4. Anas Younes (13)
  5. Maria Palomba (13)
  6. David Straus (12)

More People

Years
  1. 2024 (5)
  2. 2023 (7)
  3. 2022 (4)
  4. 2021 (6)
  5. 2020 (9)
  6. 2019 (8)

More Years

Publications
  1. British Journal of Haematology (79)
  2. Hepatology (5)
  3. Journal of Cellular Biochemistry (2)
  4. American Journal of Hematology (1)
  5. Annals of the New York Academy of Sciences (1)
  6. Evidence-Based Hematology (1)

More Publications

Results (93)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells
    Journal Article

    Munshi, M.; Liu, X.; Kofides, A.; Tsakmaklis, N.; Hunter, Z. R.; Guerrera, M. L.; Canning, A.; Gustine, J. N.; Liu, S.; Hatcher, J. M.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile
    Journal Article

    Shouval, R.; Goldman, A.; Flynn, J. R.; El-Moghraby, A.; Rehman, M.; Devlin, S. M.; Corona, M.; Landego, I.; Lin, R. J.; Scordo, M.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project
    Journal Article

    Civallero, M.; Schroers-Martin, J. G.; Horwitz, S.; Manni, M.; Stepanishyna, Y.; Cabrera, M. E.; Vose, J.; Spina, M.; Hitz, F.; Nagler, A.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas
    Journal Article

    Soumerai, J. D.; Diefenbach, C. S.; Jagadeesh, D.; Asch, A.; Kumar, A.; Tsai, M. L.; Jandl, T. A.; Lossos, I. S.; Kenkre, V. P.; Awan, F.; more...
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma
    Research Letter

    Stuver, R.; Noy, A.; Vardhana, S. A.; Zelenetz, A. D.; Moskowitz, A. J.
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S. E.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement
    Journal Article

    Ryan, C. E.; Zon, R. L.; Redd, R.; Fisher, D. C.; Shouval, R.; Kumar, A.; Crombie, J. L.; Sadrzadeh, H.; Kim, A. I.; Nayak, L.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenstrom macroglobulinemia
    Meeting Abstract

    Lewis, D. J.; Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Improved overall survival in stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1
    Meeting Abstract

    Collins, G. P.; Ansell, S. M.; Straus, D. J.; Connors, J. M.; Dlugosz-Danecka, M.; Kim, W. S.; Gallamini, A.; Ramchandren, R.; Friedberg, J. W.; Advani, R.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN
    Meeting Abstract

    Lewis, D. J.; Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutzu, K.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save